ArticleThe journals of gerontology. Series A, Biological sciences and medical sciences2026
Evidence for an energy conservation model of inflammaging and immunosenescence in the US Health and Retirement Study and UK Biobank.
Article in The journals of gerontology. Series A, Biological sciences and medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Inflammaging mediates testosterone declines in men while maintaining high testosterone increases mortality risk.bioRxiv : the preprint server for biology · 2026Article
Corrections and comments
- Update of
Authors and funding
4 authors.
Funding
Abstract
The development of chronic inflammation in later life (inflammaging), alongside changes in immune cell profiles and impaired pathogen defense (immunosenescence), contribute to health risk. However, these processes have been hypothesized as adaptive remodeling of the immune system in response to accumulating somatic damage. Here we consider a recently developed theoretical framework to understand their relationship: the Brain-Body Energy Conservation model of aging. This model views immunosenescence as part of an energy conserving response to the rising energy expenditure of inflammaging. This response promotes short-term survival against somatic damage at the expense of future health risk. For example, naïve T cells, which enhance defense against future infections, decline with age, while proteins that suppress the immune response to infection, including interleukin (IL)-10, increase. GDF-15, which similarly suppresses the immune response to infection and is produced in response to chronic inflammation and metabolic stress, also increases with age. We find evidence consistent with this model in the US Health and Retirement Study (HRS, n = 8 184) and UK Biobank (UKB, n = 40 510). Across both cohorts, the key inflammaging marker tumor necrosis factor receptor (TNFR1) partially mediated the age-related increases in IL-10 and GDF-15. In the HRS flow cytometry data, TNFR1 also mediated age-related decreases in naïve T cells. Finally, we assessed vulnerability to a novel future infection using the UKB medical records data on hospitalization or death from COVID-19 (n = 586 hospitalized or died). TNFR1, IL-10, and GDF-15, measured pre-pandemic, all partially mediated the age-related increased risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.